170 related articles for article (PubMed ID: 37624820)
1. The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study.
Chávez Fernández JA; Ramírez Mendoza M; Kassck Ipinaa H; Sánchez Ángeles LA; González Chávez A; Escobedo G; Méndez-García LA
PLoS One; 2023; 18(8):e0290544. PubMed ID: 37624820
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
Mostaza JM; Suárez-Fernández C; Cosín-Sales J; Gómez-Huelgas R; Brotons C; Araujo FP; Borrayo G; Ruiz E;
BMC Cardiovasc Disord; 2022 Dec; 22(1):560. PubMed ID: 36550424
[TBL] [Abstract][Full Text] [Related]
3. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
4. A polypill strategy to improve adherence: results from the FOCUS project.
Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
[TBL] [Abstract][Full Text] [Related]
5. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
6. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study.
González-Juanatey JR; Cordero A; Castellano JM; Masana L; Dalmau R; Ruiz E; Sicras-Mainar A; Fuster V
Int J Cardiol; 2022 Aug; 361():116-123. PubMed ID: 35569611
[TBL] [Abstract][Full Text] [Related]
7. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy.
Presta V; Figliuzzi I; Miceli F; Coluccia R; Fogacci F; Cicero AFG; Ferrucci A; Borghi C; Volpe M; Tocci G;
Atherosclerosis; 2019 Jun; 285():40-48. PubMed ID: 31003091
[TBL] [Abstract][Full Text] [Related]
8. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded "Double-Trouble" Lipid Profile in Overweight/Obese.
Spannella F; Giulietti F; Di Pentima C; Sarzani R
Adv Ther; 2019 Jun; 36(6):1426-1437. PubMed ID: 30953331
[TBL] [Abstract][Full Text] [Related]
10. The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico.
Gómez-Álvarez E; Verdejo J; Ocampo S; Ponte-Negretti CI; Ruíz E; Ríos MM;
Int J Cardiol Heart Vasc; 2020 Aug; 29():100545. PubMed ID: 32885029
[TBL] [Abstract][Full Text] [Related]
11. Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients.
Bhan V; Yan RT; Leiter LA; Fitchett DH; Langer A; Lonn E; Tan M; Silagy S; Goodman SG; Yan AT;
Am J Cardiol; 2010 Nov; 106(9):1270-6. PubMed ID: 21029823
[TBL] [Abstract][Full Text] [Related]
12. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.
Castellano JM; Verdejo J; Ocampo S; Rios MM; Gómez-Álvarez E; Borrayo G; Ruiz E; Ibáñez B; Fuster V;
Arch Med Res; 2019 Jan; 50(1):31-40. PubMed ID: 31101241
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Fixed-Dose Combination Therapy (Polypill) Versus Exercise to Improve the Blood-Lipid Profile: A Network Meta-analysis.
Martínez-Vizcaíno V; Amaro-Gahete FJ; Fernández-Rodríguez R; Garrido-Miguel M; Cavero-Redondo I; Pozuelo-Carrascosa DP
Sports Med; 2022 May; 52(5):1161-1173. PubMed ID: 34878638
[TBL] [Abstract][Full Text] [Related]
14. Which Amount of BMI-SDS Reduction Is Necessary to Improve Cardiovascular Risk Factors in Overweight Children?
Reinehr T; Lass N; Toschke C; Rothermel J; Lanzinger S; Holl RW
J Clin Endocrinol Metab; 2016 Aug; 101(8):3171-9. PubMed ID: 27285295
[TBL] [Abstract][Full Text] [Related]
15. Six Month Polypill Therapy Improves Lipid Profile in Patients with Previous Acute Myocardial Infarction: The Heart-Mex Study.
Méndez-García LA; González-Chávez A; Trejo-Millán F; Navarrete-Zarco HU; Carrero-Aguirre M; Meléndez G; Chávez A; Escobedo G
Arch Med Res; 2019 May; 50(4):197-206. PubMed ID: 31499480
[TBL] [Abstract][Full Text] [Related]
16. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
17. Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs.
Portela-Romero M; Cinza-Sanjurjo S; Conde-Sabarís P; Rodríguez-Mañero M; Mazón-Ramos P; Rey-Aldana D; González-Juanateyc JR
Rev Clin Esp (Barc); 2022 Mar; 222(3):131-137. PubMed ID: 34674985
[TBL] [Abstract][Full Text] [Related]
18. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.
Selak V; Webster R; Stepien S; Bullen C; Patel A; Thom S; Arroll B; Bots ML; Brown A; Crengle S; Dorairaj P; Elley CR; Grobbee DE; Harwood M; Hillis GS; Laba TL; Neal B; Peiris D; Rafter N; Reid C; Stanton A; Tonkin A; Usherwood T; Wadham A; Rodgers A
Heart; 2019 Jan; 105(1):42-48. PubMed ID: 29954855
[TBL] [Abstract][Full Text] [Related]
19. [Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey].
Vrablík M; Chmelík Z; Lánská V
Vnitr Lek; 2014 Nov; 60(11):991-7. PubMed ID: 25600047
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Reisin E; Graves JW; Yamal JM; Barzilay JI; Pressel SL; Einhorn PT; Dart RA; Retta TM; Saklayen MG; Davis BR;
J Hypertens; 2014 Jul; 32(7):1503-13; discussion 1513. PubMed ID: 24842697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
